BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 15255164)

  • 1. Irinotecan in advanced lung cancer: focus on North American trials.
    Langer CJ
    Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):17-28. PubMed ID: 15255164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The global role of irinotecan in the treatment of lung cancer: 2003 update.
    Langer CJ
    Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):30-40. PubMed ID: 12886872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
    Saijo N; Horiike A
    Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):11-6. PubMed ID: 15255163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Developed new agents for lung cancer].
    Kato Y; Saijo N
    Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):218-23. PubMed ID: 11904983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emerging world role of irinotecan in lung cancer.
    Langer CJ
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):15-21. PubMed ID: 11497227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for non-platinum chemotherapy in advanced NSCLC.
    Murren JR
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):29-34. PubMed ID: 11497229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [From ASCO and WCLC 2005 to clinical practice: "conventional" treatments].
    Fournel P
    Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S25-9. PubMed ID: 16719153
    [No Abstract]   [Full Text] [Related]  

  • 8. Irinotecan therapy for small-cell lung cancer.
    Sandler A
    Oncology (Williston Park); 2002 Apr; 16(4):419-25, 428, 433; discussion 433-4, 437-8. PubMed ID: 12017533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
    Mavroudis D
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S42-5. PubMed ID: 11924243
    [No Abstract]   [Full Text] [Related]  

  • 11. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
    Masuda N
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Irinotecan].
    Yokoyama A
    Nihon Rinsho; 2002 May; 60 Suppl 5():339-42. PubMed ID: 12101684
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of topoisomerase I inhibitors in small-cell lung cancer.
    Fukuoka M
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):9-13. PubMed ID: 11497234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan in small-cell lung cancer--Japanese trials.
    Fukuoka M; Masuda N; Kudoh S; Negoro S
    Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):57-62. PubMed ID: 10981292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
    Tumolo S; Toffoli G; Saracchini S; Lo Re G; Bruschi G; Boccieri MG
    Lung Cancer; 2001 Dec; 34 Suppl 4():S37-46. PubMed ID: 11742701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combination chemotherapy in the treatment of inoperable non-small cell lung cancer].
    Masuda N
    Gan To Kagaku Ryoho; 1997 Oct; 24 Suppl 3():379-83. PubMed ID: 9369911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase I targeting agents in small-cell lung cancer.
    Ohe Y; Saijo N
    Curr Oncol Rep; 2001 Mar; 3(2):170-8. PubMed ID: 11177750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer.
    Rocha Lima CM; Eckardt JR; Leong SS; Sherman CA; Perkel JA; Putman T; Safa AR; Bahadori HR; Green MR
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):43-50; discussion 71-2. PubMed ID: 10585008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ["State-of-the-art" chemotherapy for small-cell lung cancer].
    Negoro S
    Gan To Kagaku Ryoho; 1997 Oct; 24 Suppl 3():398-404. PubMed ID: 9369914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.